In A549 cells and primary NSCLC-1 cells, JNK1/2 phosphorylation, indicating JNK activation, was significantly increased with GDC-0349 treatment (Fig. 4e, f). The gene discussed is MAPK8; the disease is non-small cell lung carcinoma.